Pulmonary Drug Delivery Devices Market Revenue & Forecast Analysis, 2026-2035

The pulmonary drug delivery devices market size was estimated to be worth USD 57.3 billion in 2025. The market is expected to expand at a compound annual growth rate (CAGR) of 5.4% from USD 59.8 billion in 2026 to USD 96.0 billion by 2035. The market growth is driven by the increasing prevalence of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD), rising air pollution levels, growing tobacco consumption, and the increasing demand for targeted drug delivery systems. Additionally, advancements in inhalation technologies, portable nebulization systems, and smart inhaler solutions are further supporting market expansion globally.

Published: May 26, 2026
100 Pages

Market Overview

In the United States, more than 16 million people are affected by chronic obstructive pulmonary disease (COPD), significantly increasing the demand for pulmonary drug delivery devices such as inhalers and nebulizers. Additionally, the growing adoption of smart inhalers and home-based respiratory care solutions is further accelerating market growth across the country.

The pulmonary drug delivery devices market has experienced steady historical growth over the past decade, driven by technological advancements in inhalers and nebulizers, increasing healthcare awareness, and the growing geriatric population vulnerable to respiratory disorders. Key manufacturers have focused on developing breath-actuated inhalers, dry powder inhalers, and mesh nebulizers to improve drug delivery efficiency and patient compliance. For instance, in 2024, the American Lung Association reported that over 34 million Americans live with chronic lung diseases such as asthma and COPD, driving increased adoption of advanced inhalers and nebulizers across the U.S. healthcare system.

The anticipated growth of the Pulmonary Drug Delivery Devices market is fueled by increasing adoption of home-based respiratory care, rising demand for minimally invasive drug administration, and continuous innovations in smart inhalation systems integrated with digital monitoring technologies. Moreover, expanding healthcare access in emerging economies and growing pharmaceutical collaborations for inhalation therapies are anticipated to further enhance market growth through 2035. For instance, in May 2024, Gerresheimer announced a USD 180 million expansion of its medical systems manufacturing facility in Georgia, U.S., to increase production capacity for inhalers and other pulmonary drug delivery devices, highlighting the growing demand for respiratory care solutions in the country.

Pulmonary Drug Delivery Devices Market Overview

Base Year Market Size (2025): USD 57.3 Billion

CAGR: 5.4%

Forecast Year Market Size (2035): USD 96.0 Billion

Leading Region: North America

Emerging Countries: China, India, Brazil, Mexico, Saudi Arabia

Major Players:

  • GlaxoSmithKline plc

  • AstraZeneca plc

  • Boehringer Ingelheim International GmbH

  • Koninklijke Philips N.V.

  • Omron Healthcare, Inc.

Pulmonary Drug Delivery Devices Market Trends

The global pulmonary drug delivery devices market is undergoing significant transformation, driven by the increasing prevalence of chronic respiratory diseases and continuous advancements in inhalation technologies.

  • The integration of smart inhalers connected respiratory monitoring systems, and advanced nebulization technologies has improved medication adherence, therapeutic precision, and patient outcomes across respiratory care applications.

  • This technological evolution not only enhances drug deposition efficiency and patient convenience but also reduces hospitalization rates and improves long-term disease management, making pulmonary drug delivery more effective globally.

  • Additionally, the growing adoption of portable and home-based respiratory care devices is increasing demand for compact, battery-operated, and user-friendly inhalation systems. Manufacturers are focusing on developing digital inhalers with real-time adherence monitoring and dose-tracking capabilities to improve treatment compliance.

  • Moreover, increasing healthcare expenditure and rising awareness regarding early respiratory disease management are reshaping market dynamics. Hospitals, specialty clinics, and homecare providers are increasingly adopting advanced pulmonary drug delivery solutions that offer better therapeutic effectiveness and patient comfort.

  • This shift is expanding access to respiratory care, particularly in emerging economies, while supporting healthcare modernization and improving patient preference for non-invasive drug delivery approaches.

Collectively, these advancements are expected to significantly propel market growth, foster technological innovation, and strengthen the global footprint of the pulmonary drug delivery devices industry in the coming years.

Pulmonary Drug Delivery Devices Market Analysis

By Product Type

Inhalers dominate the market due to their portability, ease of use, and high effectiveness in respiratory drug delivery

Based on product type, the global pulmonary drug delivery devices market is segmented into inhalers, nebulizers, and accessories. The inhalers segment led the market, with a dominant market share of 63.31% in 2025.

By Application

COPD dominates due to rising respiratory disease cases.

Based on application, the global pulmonary drug delivery devices market is segmented into asthma, cystic fibrosis, chronic obstructive pulmonary disease (COPD), allergic rhinitis, pulmonary arterial hypertension, and others. The chronic obstructive pulmonary disease (COPD) segment led the market, with a significant market share in 2025.

By End-use

Hospitals lead due to advanced respiratory care facilities and high patient treatment volumes

Based on end-use, the global pulmonary drug delivery devices market is segmented into hospitals, ambulatory surgical centers, specialty clinics, and others. The hospitals segment led the market, with a dominant market share in 2025.

Regional Analysis

North America dominates the market with strong respiratory care infrastructure and high adoption of advanced inhalation therapies

North America held the largest share of 45.92% in the global pulmonary drug delivery devices market in 2025.

Europe emerges as a significant market supported by increasing respiratory disease prevalence and growing adoption of technologically advanced inhalation devices

Europe maintained the second-largest position in the global pulmonary drug delivery devices market, fueled by rising healthcare expenditure, growing awareness regarding respiratory disease management, and strong presence of major pharmaceutical and medical device manufacturers.

Key Companies Profiled

The competitive landscape of the global pulmonary drug delivery devices market is characterized by strong competition among pharmaceutical companies, respiratory device manufacturers, and healthcare technology providers. The leading key players in the industry such as GlaxoSmithKline plc, AstraZeneca plc, Boehringer Ingelheim International GmbH, Koninklijke Philips N.V., and Omron Healthcare, Inc. collectively hold a significant share in the market. Their dominance is driven by extensive respiratory therapy portfolios, advanced inhalation technologies, and strong global distribution networks.

The market is also witnessing the emergence of regional manufacturers offering cost-effective nebulizers and inhalation systems. Additionally, increasing investments in smart inhalers, digital respiratory monitoring platforms, and portable drug delivery technologies are intensifying competition, pushing companies to improve patient adherence, device efficiency, and therapeutic effectiveness.

Pulmonary Drug Delivery Devices Market Companies:

Several prominent players driving innovation and growth in the pulmonary drug delivery devices industry are as follows:

  • 3M Company

  • Aerogen Ltd.

  • AptarGroup, Inc.

  • AstraZeneca plc

  • Becton, Dickinson and Company

  • Boehringer Ingelheim International GmbH

  • Cipla Ltd.

  • GE HealthCare Technologies Inc.

  • GlaxoSmithKline plc

  • Koninklijke Philips N.V.

  • Medline Industries, LP

  • Merck & Co., Inc.

  • Novartis AG

  • Omron Healthcare, Inc.

  • PARI GmbH

  • Pfizer Inc.

  • ResMed Inc.

  • Teva Pharmaceutical Industries Ltd.

  • Vectura Group plc

  • Viatris Inc.

Market Segmentation

This study provides revenue growth and emerging trends across global, regional, and country levels from 2021 to 2035, segmenting the Pulmonary Drug Delivery Devices Market by-

Product Type (Revenue in USD Million, 2021 - 2035)

  • Inhalers

  • Nebulizers

  • Accessories

Application (Revenue in USD Million, 2021 - 2035)

  • Asthma

  • Cystic Fibrosis

  • Chronic Obstructive Pulmonary Disease (COPD)

  • Allergic Rhinitis

  • Pulmonary Arterial Hypertension

  • Others

End-use (Revenue in USD Million, 2021 - 2035)

  • Hospitals

  • Ambulatory Surgical Centers

  • Specialty Centers

  • Others

Regional (Revenue in USD Million, 2021 - 2035)

  • North America

    • U.S.

    • Canada

  • Europe

    • U.K.

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

    • Switzerland

    • Netherlands

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • Thailand

    • South Korea

    • Indonesia

  • Latin America

    • Brazil

    • Mexico

    • Argentina

    • Colombia

  • Middle East and Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait

Table of Content

1. Methodology and Scope

1.1. Scope of the Study

1.1.1. Market Segmentation

1.1.2. Market Definition

1.1.3. Inclusions and Exclusions of the Study

1.2. Research Design

1.2.1. Base Year, Historical Data, and Forecast Period

1.2.2. Data Collection Methods

1.2.2.1. Secondary Sources

1.2.2.2. Primary Sources

1.2.3. Research Methodology

1.2.3.1. Base Year Calculation/ Parent Market Analysis, Company/ Brand Share Analysis, 2025 (Top-down Approach)

1.2.3.2. Volume-Price Approach (Bottom-up Approach)

1.2.3.3. Data Triangulation

1.2.4. Forecasting Model

1.3. Research Assumptions

1.4. Validation and Data Quality Control

1.5. List of Primary Sources

1.6. List of Secondary Sources

2. Executive Summary

2.1. Market Overview

2.2. Segment Snapshot

2.3. Competitive Landscape Snapshot

3. Industry Outlook

3.1. Industry Ecosystem Analysis

3.2. Parent/ Ancillary Market Analysis

3.3. Market Dynamics

3.3.1. Drivers

3.3.2. Restraints/ Challenges

3.3.3. Opportunities

3.4. Consumer Behaviour Analysis

3.5. Value Chain Analysis

3.6. Technology Roadmap

3.7. Porters Analysis

3.8. PESTLE Analysis

4. Market Estimates and Forecasts, By Product Type, 2021 - 2035 (Market Size in USD Mn, Volume in Absolute Number)

4.1. Inhalers

4.2. Nebulizers

4.3. Accessories

5. Market Estimates and Forecasts, By Application, 2021 – 2035 (USD Mn)

5.1. Asthma

5.2. Cystic Fibrosis

5.3. Chronic Obstructive Pulmonary Disease (COPD)

5.4. Allergic Rhinitis

5.5. Pulmonary Arterial Hypertension

5.6. Others

6. Market Estimates and Forecasts, By End-use, 2021 – 2035 (USD Mn)

6.1. Hospitals

6.2. Ambulatory Surgical Centers

6.3. Specialty Centers

6.4. Others

7. Market Estimates and Forecasts, By Region, 2021 - 2035 (USD Mn)

7.1. North America

7.1.1. U.S.

7.1.1.1. U.S. Pulmonary Drug Delivery Devices Market Estimates and Forecasts to 2035 (USD Mn)

7.1.1.2. Market Dynamics

7.1.1.3. Competitive Landscape

7.1.1.4. Regulatory Framework

7.1.1.5. Reimbursement Scenario

7.1.2. Canada

7.1.2.1. Canada Pulmonary Drug Delivery Devices Market Estimates and Forecasts to 2035 (USD Mn)

7.1.2.2. Market Dynamics

7.1.2.3. Competitive Landscape

7.1.2.4. Regulatory Framework

7.1.2.5. Reimbursement Scenario

7.2. Europe

7.2.1. Germany

7.2.1.1. Germany Pulmonary Drug Delivery Devices Market Estimates and Forecasts to 2035 (USD Mn)

7.2.1.2. Market Dynamics

7.2.1.3. Competitive Landscape

7.2.1.4. Regulatory Framework

7.2.1.5. Reimbursement Scenario

7.2.2. U.K.

7.2.2.1. UK Pulmonary Drug Delivery Devices Market Estimates and Forecasts to 2035 (USD Mn)

7.2.2.2. Market Dynamics

7.2.2.3. Competitive Landscape

7.2.2.4. Regulatory Framework

7.2.2.5. Reimbursement Scenario

7.2.3. France

7.2.3.1. France Pulmonary Drug Delivery Devices Market Estimates and Forecasts to 2035 (USD Mn)

7.2.3.2. Market Dynamics

7.2.3.3. Competitive Landscape

7.2.3.4. Regulatory Framework

7.2.3.5. Reimbursement Scenario

7.2.4. Italy

7.2.4.1. Italy Pulmonary Drug Delivery Devices Market Estimates and Forecasts to 2035 (USD Mn)

7.2.4.2. Market Dynamics

7.2.4.3. Competitive Landscape

7.2.4.4. Regulatory Framework

7.2.4.5. Reimbursement Scenario

7.2.5. Spain

7.2.5.1. Spain Pulmonary Drug Delivery Devices Market Estimates and Forecasts to 2035 (USD Mn)

7.2.5.2. Market Dynamics

7.2.5.3. Competitive Landscape

7.2.5.4. Regulatory Framework

7.2.5.5. Reimbursement Scenario

7.2.6. Sweden

7.2.6.1. Sweden Pulmonary Drug Delivery Devices Market Estimates and Forecasts to 2035 (USD Mn)

7.2.6.2. Market Dynamics

7.2.6.3. Competitive Landscape

7.2.6.4. Regulatory Framework

7.2.6.5. Reimbursement Scenario

7.2.7. Norway

7.2.7.1. Norway Pulmonary Drug Delivery Devices Market Estimates and Forecasts to 2035 (USD Mn)

7.2.7.2. Market Dynamics

7.2.7.3. Competitive Landscape

7.2.7.4. Regulatory Framework

7.2.7.5. Reimbursement Scenario

7.2.8. Denmark

7.2.8.1. Denmark Pulmonary Drug Delivery Devices Market Estimates and Forecasts to 2035 (USD Mn)

7.2.8.2. Market Dynamics

7.2.8.3. Competitive Landscape

7.2.8.4. Regulatory Framework

7.2.8.5. Reimbursement Scenario

7.2.9. Switzerland

7.2.9.1. Switzerland Pulmonary Drug Delivery Devices Market Estimates and Forecasts to 2035 (USD Mn)

7.2.9.2. Market Dynamics

7.2.9.3. Competitive Landscape

7.2.9.4. Regulatory Framework

7.2.9.5. Reimbursement Scenario

7.2.10. Netherlands

7.2.10.1. Netherlands Pulmonary Drug Delivery Devices Market Estimates and Forecasts to 2035 (USD Mn)

7.2.10.2. Market Dynamics

7.2.10.3. Competitive Landscape

7.2.10.4. Regulatory Framework

7.2.10.5. Reimbursement Scenario

7.2.11. Rest of Europe

7.2.11.1. Rest of Europe Pulmonary Drug Delivery Devices Market Estimates and Forecasts to 2035 (USD Mn)

7.2.11.2. Market Dynamics

7.2.11.3. Competitive Landscape

7.2.11.4. Regulatory Framework

7.2.11.5. Reimbursement Scenario

7.3. Asia Pacific

7.3.1. China

7.3.1.1. China Pulmonary Drug Delivery Devices Market Estimates and Forecasts to 2035 (USD Mn)

7.3.1.2. Market Dynamics

7.3.1.3. Competitive Landscape

7.3.1.4. Regulatory Framework

7.3.1.5. Reimbursement Scenario

7.3.2. Japan

7.3.2.1. Japan Pulmonary Drug Delivery Devices Market Estimates and Forecasts to 2035 (USD Mn)

7.3.2.2. Market Dynamics

7.3.2.3. Competitive Landscape

7.3.2.4. Regulatory Framework

7.3.2.5. Reimbursement Scenario

7.3.3. India

7.3.3.1. India Pulmonary Drug Delivery Devices Market Estimates and Forecasts to 2035 (USD Mn)

7.3.3.2. Market Dynamics

7.3.3.3. Competitive Landscape

7.3.3.4. Regulatory Framework

7.3.3.5. Reimbursement Scenario

7.3.4. Australia

7.3.4.1. Australia Pulmonary Drug Delivery Devices Market Estimates and Forecasts to 2035 (USD Mn)

7.3.4.2. Market Dynamics

7.3.4.3. Competitive Landscape

7.3.4.4. Regulatory Framework

7.3.4.5. Reimbursement Scenario

7.3.5. South Korea

7.3.5.1. South Korea Pulmonary Drug Delivery Devices Market Estimates and Forecasts to 2035 (USD Mn)

7.3.5.2. Market Dynamics

7.3.5.3. Competitive Landscape

7.3.5.4. Regulatory Framework

7.3.5.5. Reimbursement Scenario

7.3.6. Thailand

7.3.6.1. Thailand Pulmonary Drug Delivery Devices Market Estimates and Forecasts to 2035 (USD Mn)

7.3.6.2. Market Dynamics

7.3.6.3. Competitive Landscape

7.3.6.4. Regulatory Framework

7.3.6.5. Reimbursement Scenario

7.3.7. Indonesia

7.3.7.1. Indonesia Pulmonary Drug Delivery Devices Market Estimates and Forecasts to 2035 (USD Mn)

7.3.7.2. Market Dynamics

7.3.7.3. Competitive Landscape

7.3.7.4. Regulatory Framework

7.3.7.5. Reimbursement Scenario

7.3.8. Rest of Asia Pacific

7.3.8.1. Rest of Asia Pacific Pulmonary Drug Delivery Devices Market Estimates and Forecasts to 2035 (USD Mn)

7.3.8.2. Market Dynamics

7.3.8.3. Competitive Landscape

7.3.8.4. Regulatory Framework

7.3.8.5. Reimbursement Scenario

7.4. Latin America

7.4.1. Brazil

7.4.1.1. Brazil Pulmonary Drug Delivery Devices Market Estimates and Forecasts to 2035 (USD Mn)

7.4.1.2. Market Dynamics

7.4.1.3. Competitive Landscape

7.4.1.4. Regulatory Framework

7.4.1.5. Reimbursement Scenario

7.4.2. Mexico

7.4.2.1. Mexico Pulmonary Drug Delivery Devices Market Estimates and Forecasts to 2035 (USD Mn)

7.4.2.2. Market Dynamics

7.4.2.3. Competitive Landscape

7.4.2.4. Regulatory Framework

7.4.2.5. Reimbursement Scenario

7.4.3. Argentina

7.4.3.1. Argentina Pulmonary Drug Delivery Devices Market Estimates and Forecasts to 2035 (USD Mn)

7.4.3.2. Market Dynamics

7.4.3.3. Competitive Landscape

7.4.3.4. Regulatory Framework

7.4.3.5. Reimbursement Scenario

7.4.4. Colombia

7.4.4.1. Colombia Pulmonary Drug Delivery Devices Market Estimates and Forecasts to 2035 (USD Mn)

7.4.4.2. Market Dynamics

7.4.4.3. Competitive Landscape

7.4.4.4. Regulatory Framework

7.4.4.5. Reimbursement Scenario

7.5. Middle East and Africa

7.5.1. South Africa

7.5.1.1. South Africa Pulmonary Drug Delivery Devices Market Estimates and Forecasts to 2035 (USD Mn)

7.5.1.2. Market Dynamics

7.5.1.3. Competitive Landscape

7.5.1.4. Regulatory Framework

7.5.1.5. Reimbursement Scenario

7.5.2. Saudi Arabia

7.5.2.1. Saudi Arabia Pulmonary Drug Delivery Devices Market Estimates and Forecasts to 2035 (USD Mn)

7.5.2.2. Market Dynamics

7.5.2.3. Competitive Landscape

7.5.2.4. Regulatory Framework

7.5.2.5. Reimbursement Scenario

7.5.3. UAE

7.5.3.1. UAE Pulmonary Drug Delivery Devices Market Estimates and Forecasts to 2035 (USD Mn)

7.5.3.2. Market Dynamics

7.5.3.3. Competitive Landscape

7.5.3.4. Regulatory Framework

7.5.3.5. Reimbursement Scenario

7.5.4. Kuwait

7.5.4.1. Kuwait Pulmonary Drug Delivery Devices Market Estimates and Forecasts to 2035 (USD Mn)

7.5.4.2. Market Dynamics

7.5.4.3. Competitive Landscape

7.5.4.4. Regulatory Framework

7.5.4.5. Reimbursement Scenario

7.5.5. Rest of Middle East and Africa

7.5.5.1. Rest of MEA Pulmonary Drug Delivery Devices Market Estimates and Forecasts to 2035 (USD Mn)

7.5.5.2. Market Dynamics

7.5.5.3. Competitive Landscape

7.5.5.4. Regulatory Framework

7.5.5.5. Reimbursement Scenario

8. Competitive Landscape

8.1. Company Market Share Analysis, 2025

8.2. Company Tier Structure

8.3. List of Major Suppliers, By Key Countries

8.4. Key Company Positioning Analysis

8.5. Company Profile

8.5.1. 3M Company

8.5.2. Aerogen Ltd.

8.5.3. AptarGroup, Inc.

8.5.4. AstraZeneca plc

8.5.5. Becton, Dickinson and Company

8.5.6. Boehringer Ingelheim International GmbH

8.5.7. Cipla Ltd.

8.5.8. GE HealthCare Technologies Inc.

8.5.9. GlaxoSmithKline plc

8.5.10. Koninklijke Philips N.V.

8.5.11. Medline Industries, LP

8.5.12. Merck & Co., Inc.

8.5.13. Novartis AG

8.5.14. Omron Healthcare, Inc.

8.5.15. PARI GmbH

8.5.16. Pfizer Inc.

8.5.17. ResMed Inc.

8.5.18. Teva Pharmaceutical Industries Ltd.

8.5.19. Vectura Group plc

8.5.20. Viatris Inc.

8.6. Key Development Strategies

8.6.1. New Product Launches

8.6.2. Mergers and Acquisition

8.6.3. Partnerships and Collaborations

8.6.4. Expansion Plans

9. Analyst Perspective

10. Related Reports

Related Research

U.S. Botulinum Toxin Market Revenue & Forecast Analysis, 2026-2035

May 30, 2026View

U.S. CAD CAM Dental Milling Market Revenue & Forecast Analysis, 2026-2035

May 30, 2026View

U.S. Dental X-Ray Market Revenue & Forecast Analysis

May 29, 2026View

Revolution Insights Briefs

Stay informed with updates on related market reports and key industry topics.